Two severe adverse events were reported: viral meningitis (in cagrilintide 1.2 mg + semaglutide 2.4 mg) and an increase in serum creatinine (in placebo + semaglutide 2.4 mg), but both events were deemed unrelated to study treatment by the study investigator
Batch traceability
J Immunol 165(11):65766582 Barreca MM, Spinello W, Cavalieri V, Turturici G, Sconzo G, Kaur P, Tinnirello R, Asea AA, Geraci F (2017) Extracellular Hsp70 enhances mesoangioblast migration via an autocrine signaling pathway
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
Of these, 12.5 percent were performed in patients with ALD, and 5.8 percent were performed in patients with ALD and a concurrent infection with the hepatitis C virus (HCV), making ALD the second most frequent reason (after HCV infection alone) for transplantation